Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right now Image courtesy of ResMed ResMed CEO Mick Farrells stance on the issue is that the latest advances in both Big Tech and Big Pharma can potentially bring incredible numbers of new patients into the healthcare system where ResMed is uniquely positioned to provide ongoing care at home. Patients are voting with their wallets and respiratory therapists and physicians are voting with their recommendations and their prescriptions. During the companys first-quarter earnings call, Farrell said the company is laser-focused on growing the market to help people get on the therapy they need and on a pathway to better sleep, better health, and better long-term care
They often support the need for advanced treatments or referrals (like bariatric surgery)
The back of a middle shelf is the most stable location
See if you qualify for GLP-1 treatment References Phelps NH, Singleton RK, Zhou B, et al
The Research Landscape Retatrutide has moved through published research relatively quickly
A 2022 Diabetes Care study found that nausea was reported by 44% of semaglutide users in week one but only 6% still had it by week 20
